Akums Drugs and Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals has submitted its annual disclosure under SEBI's Takeover Regulations for FY ending 31 March 2025. Promoter and Managing Director Sanjeev Jain declared that he and all persons acting in concert have not created any encumbrance (pledge, charge, or lock-in) on shares held by them in the company during the year. The filing also lists 30 entities and individuals in the promoter and promoter group, including family members, trusts, and group companies. This is a routine annual compliance submission confirming status quo on share encumbrances by the promoter group.
This is a neutral-to-positive disclosure for shareholders, as it confirms the promoter group did not pledge or lock in any of their shares during the year. No immediate impact on stock price is expected, but it reassures investors about promoter financial standing.